UCB Performance degli utili passati
Criteri Il passato verificati 5/6
UCB ha registrato una crescita degli utili a un tasso medio annuo di 8.3%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 8.8%. I ricavi sono stati in crescita a un tasso medio annuo di 5.1%. Il ritorno sul capitale proprio di UCB è 14.3% e ha margini netti di 20.1%.
Informazioni chiave
8.26%
Tasso di crescita degli utili
8.08%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 12.39% |
| Tasso di crescita dei ricavi | 5.05% |
| Rendimento del capitale proprio | 14.34% |
| Margine netto | 20.13% |
| Prossimo aggiornamento sugli utili | 30 Jul 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • May 15
UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential
Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
Aggiornamento della narrazione • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.Aggiornamento della narrazione • Apr 16
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.Aggiornamento della narrazione • Apr 01
UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.Aggiornamento della narrazione • Mar 18
UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
Aggiornamento della narrazione • Mar 04
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.Aggiornamento della narrazione • Feb 18
UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.Aggiornamento della narrazione • Feb 04
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.Aggiornamento della narrazione • Jan 21
UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.Aggiornamento della narrazione • Jan 07
UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.Aggiornamento della narrazione • Dec 18
UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.Aggiornamento della narrazione • Dec 04
UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.Aggiornamento della narrazione • Nov 20
UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.Articolo di analisi • Nov 11
UCB (EBR:UCB) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aggiornamento della narrazione • Nov 06
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.Aggiornamento della narrazione • Oct 22
Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.Articolo di analisi • Oct 14
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...Aggiornamento della narrazione • Oct 08
Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.Aggiornamento della narrazione • Sep 24
Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.Aggiornamento della narrazione • Aug 27
Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.Articolo di analisi • Jul 17
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
Nuova narrazione • Mar 02
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come UCB guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 7,741 | 1,558 | 2,749 | 1,822 |
| 30 Sep 25 | 7,295 | 1,445 | 2,654 | 1,837 |
| 30 Jun 25 | 6,848 | 1,332 | 2,559 | 1,852 |
| 31 Mar 25 | 6,500 | 1,199 | 2,453 | 1,817 |
| 31 Dec 24 | 6,152 | 1,065 | 2,347 | 1,781 |
| 30 Sep 24 | 5,803 | 653 | 2,190 | 1,721 |
| 30 Jun 24 | 5,454 | 240 | 2,033 | 1,660 |
| 31 Mar 24 | 5,318 | 292 | 1,929 | 1,645 |
| 31 Dec 23 | 5,182 | 343 | 1,824 | 1,630 |
| 30 Jun 23 | 5,111 | 332 | 1,726 | 1,631 |
| 31 Mar 23 | 5,279 | 376 | 1,720 | 1,651 |
| 31 Dec 22 | 5,447 | 420 | 1,714 | 1,670 |
| 30 Jun 22 | 5,854 | 887 | 1,695 | 1,674 |
| 31 Mar 22 | 5,816 | 971 | 1,625 | 1,652 |
| 31 Dec 21 | 5,777 | 1,055 | 1,554 | 1,629 |
| 30 Sep 21 | 5,647 | 996 | 1,506 | 1,631 |
| 30 Jun 21 | 5,517 | 936 | 1,458 | 1,633 |
| 31 Mar 21 | 5,432 | 834 | 1,438 | 1,601 |
| 31 Dec 20 | 5,347 | 732 | 1,417 | 1,569 |
| 30 Jun 20 | 5,198 | 743 | 1,368 | 1,393 |
| 31 Mar 20 | 5,056 | 767 | 1,336 | 1,333 |
| 31 Dec 19 | 4,913 | 790 | 1,303 | 1,272 |
| 30 Jun 19 | 4,686 | 652 | 1,212 | 1,229 |
| 31 Mar 19 | 4,659 | 722 | 1,178 | 1,195 |
| 31 Dec 18 | 4,632 | 792 | 1,144 | 1,161 |
| 30 Jun 18 | 4,569 | 872 | 1,105 | 1,083 |
| 31 Mar 18 | 4,522 | 812 | 1,119 | 1,070 |
| 31 Dec 17 | 4,474 | 752 | 1,132 | 1,057 |
| 30 Sep 17 | 4,400 | 708 | 1,138 | 1,047 |
| 30 Jun 17 | 4,325 | 664 | 1,144 | 1,036 |
| 31 Mar 17 | 4,236 | 604 | 1,133 | 1,028 |
| 31 Dec 16 | 4,147 | 543 | 1,122 | 1,020 |
| 30 Sep 16 | 4,051 | 439 | 1,111 | 1,022 |
| 30 Jun 16 | 3,955 | 334 | 1,099 | 1,023 |
| 31 Mar 16 | 3,916 | 299 | 1,098 | 1,030 |
| 31 Dec 15 | 3,876 | 264 | 1,096 | 1,037 |
| 30 Sep 15 | 3,773 | 266 | 1,069 | 999 |
| 30 Jun 15 | 3,670 | 268 | 1,042 | 961 |
Guadagni di qualità: UCB ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di UCB (20.1%) UCB sono più alti rispetto allo scorso anno (17.3%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di UCB sono cresciuti del 8.3% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di UCB nell'ultimo anno ( 46.3% ) supera la media quinquennale ( 8.3% all'anno).
Guadagni vs Settore: La crescita degli utili UCB nell'ultimo anno ( 46.3% ) ha superato la percentuale del settore Pharmaceuticals 16.1%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 14.3% ) di UCB è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 02:06 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
UCB SA è coperta da 40 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Charles Pitman | Barclays |
| Brian Bourdot | Barclays |
| Charles Pitman | Barclays |